Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Oxytocin - Tonix Pharmaceuticals

Next Previous
Drug Profile

Oxytocin - Tonix Pharmaceuticals

Alternative Names: Intranasal potentiated oxytocin - Tonix Pharmaceuticals; Oxytocin intranasal - Tonix Pharmaceuticals; TI-001; TI-114; TNX-1900; TNX-2900

Latest Information Update: 30 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Trigemina
  • Developer Massachusetts General Hospital; Tonix Pharmaceuticals Holding Corp; Trigemina
  • Class Amides; Amines; Analgesics; Antihaemorrhagics; Antihyperglycaemics; Antimigraines; Behavioural disorder therapies; Hormones; Macrocyclic lactams; Obesity therapies; Oxytocics; Pyrrolidines
  • Mechanism of Action Calcitonin gene-related peptide antagonists; Oxytocin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Prader-Willi syndrome
  • New Molecular Entity No
  • Available For Licensing Yes - Prader-Willi syndrome

Highest Development Phases

  • Phase II Autism spectrum disorder; Binge-eating disorder; Obesity; Social phobia
  • Phase I Diabetes insipidus; Prader-Willi syndrome
  • Phase 0 Pain
  • No development reported Diabetes mellitus; Glucose intolerance; Headache; Insulin resistance; Trigeminal neuralgia
  • Discontinued Migraine

Most Recent Events

  • 13 Mar 2026 Tonix Pharmaceuticals Holding Corp plans a phase II trial for Prader-Willi syndrome (In children, In adolescents) ( Intranasal) in the first quarter of 2027
  • 29 Sep 2025 Tonix Pharmaceuticals expects to receive Priority Review Voucher upon approval for Prader-Willi Syndrome
  • 10 Sep 2025 Phase-I clinical trials in Diabetes insipidus in USA (Intranasal) (NCT04789148)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top